{"id":"insulin-semaglutide-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination leverages two complementary pathways in glucose homeostasis. Insulin directly lowers blood glucose by promoting cellular uptake and storage. Semaglutide, a GLP-1 receptor agonist, stimulates insulin secretion in response to meals, suppresses glucagon secretion, and delays gastric emptying, thereby improving postprandial glucose control and promoting weight loss. Together, they address both fasting and postprandial hyperglycemia in type 2 diabetes.","oneSentence":"Insulin provides glucose control via the insulin receptor, while semaglutide activates GLP-1 receptors to enhance insulin secretion, reduce glucagon, and slow gastric emptying.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:21.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (phase 3 combination therapy)"}]},"trialDetails":[{"nctId":"NCT07361874","phase":"NA","title":"IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-05","conditions":"Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's","enrollment":75},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT06975111","phase":"PHASE2, PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":"Menopause, Menopause Hot Flashes, Menopause Related Conditions","enrollment":200},{"nctId":"NCT05984238","phase":"NA","title":"A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT05305794","phase":"PHASE3","title":"Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-07-12","conditions":"Double Diabetes","enrollment":76},{"nctId":"NCT05352815","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-06-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1291},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT03919929","phase":"PHASE2, PHASE3","title":"Treating PCOS With Semaglutide vs Active Lifestyle Intervention","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-05-03","conditions":"PCOS, Adolescent Obesity, NAFLD","enrollment":60},{"nctId":"NCT06282458","phase":"PHASE2","title":"Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt","status":"COMPLETED","sponsor":"Veru Inc.","startDate":"2024-04-29","conditions":"Muscle Loss, Obesity","enrollment":168},{"nctId":"NCT05813912","phase":"PHASE3","title":"A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-22","conditions":"Diabetes Mellitus, Type 2","enrollment":148},{"nctId":"NCT06909006","phase":"PHASE3","title":"Semaglutide Treatment in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-10","conditions":"Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM)","enrollment":122},{"nctId":"NCT05259033","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-04-11","conditions":"Diabetes Mellitus, Type 2","enrollment":683},{"nctId":"NCT05071898","phase":"PHASE1","title":"Pharmacogenetics of Response to GLP1R Agonists","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2022-04-11","conditions":"Obesity, Diabetes Type 2","enrollment":600},{"nctId":"NCT06411210","phase":"PHASE2","title":"Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-07-16","conditions":"Diabetes type1, Obesity","enrollment":54},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT06487832","phase":"NA","title":"Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-07-01","conditions":"Normal Weight, Overweight and Obesity, Insulin Sensitivity","enrollment":60},{"nctId":"NCT06894784","phase":"PHASE3","title":"A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-04","conditions":"Diabetes Type 1","enrollment":36},{"nctId":"NCT06856291","phase":"","title":"Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance","status":"RECRUITING","sponsor":"ETH Zurich","startDate":"2025-03-15","conditions":"Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance","enrollment":40},{"nctId":"NCT05205928","phase":"PHASE2, PHASE3","title":"Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-10-02","conditions":"Type 1 Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT06082063","phase":"PHASE3","title":"Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes","status":"RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-07-01","conditions":"Cardiovascular Diseases, Heart Failure, Type 1 Diabetes","enrollment":2000},{"nctId":"NCT06387199","phase":"PHASE2, PHASE3","title":"Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-12-01","conditions":"Type 1 Diabetes, Diabetes Mellitus","enrollment":26},{"nctId":"NCT03789578","phase":"PHASE1","title":"A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-17","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06461377","phase":"PHASE4","title":"The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-06-13","conditions":"Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)","enrollment":50},{"nctId":"NCT06072963","phase":"PHASE2","title":"COMMETS- Combination MCI Metabolic Syndrome","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-01-30","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome","enrollment":80},{"nctId":"NCT06120556","phase":"","title":"Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2023-06-10","conditions":"Diabetes Mellitus, Type 2","enrollment":130},{"nctId":"NCT04572165","phase":"","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","status":"UNKNOWN","sponsor":"Novo Nordisk A/S","startDate":"2021-01-26","conditions":"Diabetes Mellitus, Type 2","enrollment":600000},{"nctId":"NCT06057077","phase":"PHASE1, PHASE2","title":"Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus","status":"UNKNOWN","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2024-01-01","conditions":"Type 1 Diabetes","enrollment":120},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05857085","phase":"PHASE4","title":"Novel Therapeutics and Endothelial Dysfunction in T1DM Patients","status":"COMPLETED","sponsor":"General and Teaching Hospital Celje","startDate":"2021-12-15","conditions":"Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers","enrollment":90},{"nctId":"NCT03689374","phase":"PHASE3","title":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2274},{"nctId":"NCT05249881","phase":"EARLY_PHASE1","title":"\"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan.\"","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2022-03-10","conditions":"Diabetes Mellitus, Type 2, Weight Change, Body","enrollment":300},{"nctId":"NCT05147896","phase":"NA","title":"Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2022-05-01","conditions":"Diabetes Mellitus, Type 2, Atherosclerosis","enrollment":100},{"nctId":"NCT04383197","phase":"NA","title":"Exercise and GLP-1 RA on Insulin Secretion","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2019-12-10","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT03021187","phase":"PHASE3","title":"Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-02-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":731}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin + semaglutide treatment","genericName":"Insulin + semaglutide treatment","companyName":"Centre Hospitalier Universitaire Dijon","companyId":"centre-hospitalier-universitaire-dijon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin provides glucose control via the insulin receptor, while semaglutide activates GLP-1 receptors to enhance insulin secretion, reduce glucagon, and slow gastric emptying. Used for Type 2 diabetes mellitus (phase 3 combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}